Seeking Alpha Portfolio App for iPad
Dividends & Income
This user currently has no profile.
I consider myself a 50/50 technical/fundamental trader and investor. I have carved a niche in analyzing small cap biotechnology companies and analyzing trial data, design and company structure. I mainly trade catalyst-driven stocks with good cash positions and promising therapies. Overall, my specialty is trial data. Over the past 6 years of research and investing, I have learned of the many ways to make money trading these extremely volatile and speculative biotech plays, particularly by making the best assumptions and educated guesses possible on trial data and company structure and management. I play the FDA calendar and pick the best companies possible for run-ups to data. I also do research for Stockmatusow.com, and
collaborate with Scott Matusow and Kyle Dennis on articles and trade calls.
Independent / boutique research firm analyst.
Commodities, Energy stocks, Retirement savings
Currently, there is no company profile for Rager500.
Currently, there are no blog details for Rager500.
Currently, there are no book details for Rager500.
I Think You Mislabeled Your...
Can Europe Pull Germany From Fantasy Land?
MY FRIEND AMEN!@ The truth....
GE CEO Stuck Inside Wet Paper Bag
The Opinion Leaders
Xignite quote data
© 2014 Seeking Alpha